SEC Form 4 · accession 0000899243-17-013113
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — Chief Financial Officer
Period of report
May 12, 2017
Accepted (ET)
May 15, 2017 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | May 12, 2017 | P | 5,000 | $19.842 | A | 5,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades in prices ranging from $19.83 to $19.85, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.